Baroda BNP Paribas Innovation Fund
(An open-ended equity scheme investing in innovation theme)
Baroda BNP Paribas Innovation Fund
(An open-ended equity scheme investing in innovation theme)
June 2026

June 2026


Investment Objective

The investment objective of the scheme is to seek long term capital appreciation by investing at least 80% of its net assets in equity/equity related instruments of companies focusing and benefitting from innovation. However, there is no assurance that the investment objective of the Scheme will be achieved.

NAV Details (As on June 30, 2026)
Regular Plan-IDCW : ₹ 12.9673
Regular Plan-Growth Option : ₹ 13.0991
Direct Plan-IDCW : ₹ 13.5501
Direct Plan-Growth Option : ₹ 13.5501
 
Benchmark Index (AMFI Tier 1)

Nifty 500 TRI

Date of Allotment

March 5, 2024

Fund Manager
Fund Manager Managing fund since Experience
Mr. Jitendra Sriram** 01-Jul-26 27 years
Mr. Abhay Joshi** 01-Jul-26 2.5 years

**Mr. Jitendra Sriram & Mr. Abhay Joshi was appointed as Fund Manager w.e.f July 1, 2026 in place of Mr. Sanjay Chawla and Mr. Ankeet Pandya.

Load Structure

Exit Load: • If units of the Scheme are redeemed or switched out up to 10% of the units within 1 year from the date of allotment - Nil. • If units of the scheme are redeemed or switched out in excess of the limit within 1 year from the date of allotment - 1% of the applicable NAV. • If units of scheme are redeemed or switched out after 1 year from the date of allotment - Nil.

For detailed load structure please refer Scheme Information Document.

Lumpsum Details

Minimum Amount: Lumpsum investment:
₹ 1,000 and in multiples of ₹ 1 thereafter.
Minimum Additional Application Amount:₹ 1,000 and in multiples of ₹ 1 thereafter.


Monthly AAUM## As on June 30, 2026 : ₹ 870.44 Crores
AUM## As on June 30, 2026 : ₹ 886.81 Crores

## including inter-scheme Investments, if any, by other schemes of Baroda BNP Paribas Mutual Fund, as may be applicable

EQUITY HOLDINGS % of Net Assets
Pharmaceuticals & Biotechnology 13.04%
Acutaas Chemicals Limited 3.98%
Divi's Laboratories Limited 2.97%
Glenmark Pharmaceuticals Limited 2.49%
Lupin Limited 2.45%
Concord Biotech Limited 1.15%
Chemicals & Petrochemicals 7.94%
Linde India Limited 4.56%
Navin Fluorine International Limited 3.38%
Capital Markets 7.74%
Multi Commodity Exchange of India Limited 3.84%
BSE Limited 1.96%
Billionbrains Garage Ventures Ltd 1.94%
Retailing 7.74%
Lenskart Solutions Limited 2.61%
FSN E-Commerce Ventures Limited 2.59%
Eternal Limited 2.54%
Financial Technology (Fintech) 7.33%
One 97 Communications Limited 3.93%
Pine Labs Limited 2.21%
PB Fintech Limited 1.19%
Automobiles 6.34%
TVS Motor Company Limited 2.79%
Mahindra & Mahindra Limited 2.25%
Ola Electric Mobility Ltd 1.30%
Electrical Equipment 5.44%
Hitachi Energy India Limited 3.54%
GE Vernova T&D India Limited 1.90%
Industrial Products 5.02%
Cummins India Limited 2.55%
Polycab India Limited 2.47%
IT - Services 4.58%
Amagi Media Labs Limited 2.69%
Sagility Limited 1.89%
Auto Components 3.55%
Bosch Limited 2.70%
Jtekt India Limited 0.85%
Aerospace & Defense 3.42%
Bharat Electronics Limited 2.55%
Aequs Limited 0.87%
IT - Software 3.30%
Fractal Analytics Ltd 1.33%
Infosys Limited 0.99%
Persistent Systems Limited 0.98%
Finance 2.83%
Bajaj Finance Limited 2.83%
Diversified 2.32%
3M India Limited 2.32%
Transport Services 2.13%
Delhivery Limited 2.13%
Telecom - Services 2.09%
Bharti Airtel Limited 2.09%
Insurance 2.07%
Max Financial Services Limited 2.07%
Banks 1.86%
Ujjivan Small Finance Bank Limited 1.86%
Leisure Services 1.72%
Travel Food Services Limited 1.72%
Other Consumer Services 1.12%
PhysicsWallah Limited 1.12%
Consumer Durables 1.06%
Amber Enterprises India Limited 1.06%
LESS THAN 0.75% EXPOSURE 2.84%
TOTAL EQUITY HOLDING 95.48%
PREFSHARE HOLDING 0.06%
6% TVS Motor Co Non Conv Rede Pref Shares 01SEP26 0.06%
FIXED INCOME HOLDINGS Rating % of Net Assets
Treasury Bill 1.12%
182 Days Tbill (MD 03/09/2026) SOV 1.12%
Total Fixed Income Holdings 1.12%
TREPS, Cash & Other Net Current Assets 3.34%
GRAND TOTAL 100.00%

Investment in Top 10 scrips constitutes 34.52% of the portfolio


For SIP Performance please click here

For Scheme Performance please click here


Pursuant to distribution under Income Distribution cum Capital Withdrawal (‘IDCW’) option, NAV of the IDCW option of the scheme(s) would fall to the extent of payout and statutory levy (if applicable). The amounts under IDCW options can be distributed out of investors capital (Equalization Reserve), which is part of sale price that represents realized gains. Past performance may or may not be sustained in future. The above stated distribution rate per unit is net distribution rate after deducting applicable taxes. The above distribution rates are on face value of ₹ 10 per unit.

BER - Regular Plan (%) 1.96%
BER - Direct Plan (%) 0.88%
Portfolio Turnover Ratio 0.69

The Total Expense Ratio (TER) is the sum of the Base Expense Ratio (BER), brokerage fees, transaction costs, and statutory levies.

No of Stocks 46
Portfolio RoE (%) 13.30
EPS Growth (%) 35.86

This product is suitable for investors who are seeking*:

➤ Long term capital appreciation
➤ Investment in equity & equity related securities of the companies that benefit from innovation theme.

*Investors should consult their financial advisers if in doubt about whether the product is suitable for them.

Scheme Riskometer^^
Investors understand that their principal will be at Very High risk


Benchmark (Tier 1) Riskometer^
Benchmark riskometer is at Very High risk


^^Riskometer For Scheme: basis it’s portfolio, ^Riskometer For Benchmark (Nifty 500 TRI): basis it’s constituents; As on June 30, 2026

For complete portfolio, kindly refer the website https://www.barodabnpparibasmf.in/
* refer Glossary page

Mutual Fund investments are subject to market risks, read all scheme related documents carefully.